454 filings
Page 2 of 23
CORRESP
10w86atv9mb8sk xsa
13 Nov 23
Correspondence with SEC
12:00am
6-K
d2a 4iqqdl6
2 Nov 23
Purple Biotech Fortifies NT219 Patent Protection
7:04am
D
mlaqz1hv4y
31 Oct 23
$5.43 mm in options / securities to be acquired, sold $5.43 mm, 1 investor
4:30pm
F-1
5vs h9pizuxbs4zzy6l
30 Oct 23
Registration statement (foreign)
4:30pm
424B3
91eukm8
19 Oct 23
Prospectus supplement
4:40pm
6-K
50dzx j9l
19 Oct 23
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
4:17pm
6-K
uf6mxszueifg
19 Oct 23
Report of Foreign Private Issuer
10:36am
424B5
ityv66soyvi
19 Oct 23
Prospectus supplement for primary offering
10:27am
6-K
ek29de57
17 Oct 23
Purple Biotech Announces $5 Million Registered Direct Offering
8:02am
424B5
9jqwzl 2sqk6on
17 Oct 23
Prospectus supplement for primary offering
7:03am
6-K
q5em74lqxgcgjdz6sg
13 Oct 23
Report of Foreign Private Issuer
7:09am
6-K
lrjq cc8y83bq4713q9a
6 Oct 23
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
8:01am
6-K
zgo4t09688fha1da3
3 Oct 23
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
8:00am
6-K
fl7olsxi2 1q7
21 Sep 23
Report of Foreign Private Issuer
8:04am
6-K
5ftj2pryycks9t
13 Sep 23
Report of Foreign Private Issuer
8:39am
6-K
ebubnz ti
22 Aug 23
Purple Biotech Reports Second Quarter 2023 Financial Results
8:22am
6-K
8q8y0wp50703mk6
11 Jul 23
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
8:20am
6-K/A
ogs06rxs0aw0
20 Jun 23
Current report (foreign) (amended)
8:00am
6-K
ctz8 zdq3n
15 Jun 23
Current report (foreign)
4:00pm
EFFECT
dlwoofds0dhjpdjr r9k
23 May 23
Notice of effectiveness
12:15am